As the popularity of GLP-1 meds like Wegovy and Zepbound grows, fewer Americans are turning to weight-loss surgeries to trim their waistlines, a new report finds.

Study of those who started taking blockbuster weight loss drugs in 2021 suggests patients need support services, not just the medications.

Drugs like Wegovy may trim your waistline but not medical costs, according to an analysis of U.S. health insurance claims shared with Reuters.

A new class of weight-loss drugs is changing the food industry, but not in the way many expected at first. They could present just as many opportunities as pitfalls. People taking the drugs do indeed eat less—especially indulgent treats.

After insurance for New York City employees began covering GLP-1 weight-loss injectables, more than 1,000 city workers and their dependents began using the drugs — and now, they're being told that coverage was accidental.

In a new study, obese kids who used GLP-1 weight-loss drugs had a 33% decline in their risk for thoughts of suicide and suicide attempts compared to adolescents who didn't.

Prescriptions of this GLP-1 class of diabetes and weight-loss medications more than doubled between 2022 and 2023, a new tally finds. "In contrast, there was a 25.6% decrease in patients undergoing metabolic bariatric surgery" during the same time period,

Meds like Wegovy are all over the news. But are they right for you, especially if you're older than the average user?By Hallie LevineAre you wondering whether you’re a candidate for one of the